IZB Munich - Innovation and Start-Up Center Biotechnology

Where the future becomes reality

+++ 30 Years of IZB: An Anniversary Marked by Innovation +++

+++ Thermosome Initiates Final Dose Level in Phase I Trial of Lead compound THE001 +++

+++ SciRhom announces first dosing in First-in-Man trial for lead program SR-878 +++

+++ Eisbach receives IND clearance for lead candidate EIS-12656, a first-in-class allosteric inhibitor of ALC1, from the FDA +++

+++ Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients. +++

+++ Tubulis presents novel preclinical data for its lead ADC candidates targeting solid tumors at AACR 2024 +++

+++ Eisbach receives USD 4.5 million investment from Cancer Focus Fund to support Phase 1/2 trial of lead candidate EIS-12656 +++

+++ Tubulis secures significant EUR 128 million Series B2 financing +++

+++ Novel small molecule drugs of the future targeting the CNS +++

+++ Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB) +++

+++ Thermosome advances Phase I trial with lead candidate THE001 to next dose level +++

+++ MorphoSys enters into Business Combination Agreement to be Acquired by medicines company Novartis +++

+++ CatalYm strengthens Board of Directors and Scientific Advisory Board with key appointments +++

+++ Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq +++

+++ MorphoSys ends the year with positive phase 3 data and successful cash capital increase of approximately EUR 102.7 million +++

+++ Oncology experts to support the development of Thermosome’s clinical candidate THE001 +++

+++ Renowned Peutinger-Collegium visits the IZB +++

+++ SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878 +++

+++ GoingPublic celebrates a quarter century of biotech +++

+++ 4SC’s resminostat receives Orphan Drug Designation from the European Medicines Agency +++

+++ Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell +++

+++ Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology +++

+++ High-Profile Clinical Advisory Board for Thermosome +++

+++ Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker +++

+++ MorphoSys’ program tulmimetostat receives FDA Fast Track designation +++

+++ adivo becomes part of the world’s leading animal health company Zoetis +++

+++ The Munich Bavaria Student Union visits the IZB +++

+++ Bind-X secures €10 million in financing as part of its Series B financing round +++

+++ Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research +++

+++ 23 students from Europe visited the IZB as part of the AMGEN Scholar Program +++

+++ M1 – Munich Medical Alliance: Becoming Germany’s No. 1 medical hub +++

+++ Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy +++

+++ Vivoryon Therapeutics highlights progress of lead candidate varoglutamstat in Alzheimer’s disease +++

+++ leon-nanodrugs welcomes Dr. Hans Frickel as new CEO +++

+++ Pioneering research projects at the 8th Life Science Pitch Day at the IZB +++

+++ Japanese delegation visits the IZB +++

+++ Bavarian biotechnology maintains its position in the crisis and continues to grow +++

+++ Biotech company Origenis welcomes Prof. Hendrik Liebers as Chairman of the Board +++

+++ Official handover ceremony at the Annual Meeting of the Max Planck Society +++

+++ Secarna appoints new Chief Business Officer +++

+++ Bicoll showcases at BIO International Convention +++

+++ Thermosome joins IMAGIO consortium to advance development of cancer therapies for soft tissue sarcoma +++

+++ Breakthrough in fluorescence microscopy at the Max Planck Institute of Biochemistry +++

+++ New preclinical data show long-term antitumor effects of Secarna Pharmaceuticals’ antisense oligonucleotide (ASO) therapies +++

+++ Biotech report by vfa: Biopharmaceuticals successfully gain market share +++

+++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa +++

+++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics +++

+++ Non-nutritive sweeteners may affect the human immune system +++

+++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” +++

+++ Invitris receives 250,000 EUR to complete spin-out from TUM +++

+++ Eisbach starts phase I clinical trial with COVID-19 antiviral +++

+++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park +++

+++ Specific packaging of DNA affects cell division +++

+++ Tubulis Enters Strategic Partnership with BMS +++

+++ Insempra launches its first functional component for consumer goods +++

+++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman +++

+++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease +++

+++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership +++

+++ adivo expands into new headquarters as first clinical study begins +++

+++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial +++

+++ Construction of the “New Hauner” at the Grosshadern Campus has started +++

+++ Insempra names new Chief Operating Officer +++

+++ Training events for project managers and biological safety officers +++

+++ The zebrafish brain as a map +++

+++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure +++

+++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris +++

+++ When life begins too early +++

+++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease +++

+++ Expansion of the Munich “science line” has started +++

+++ Enno Spillner to join Formycon as CFO +++

IZB at the media

Facts & Figures about the IZB

Laboratories and offices of the IZBThe ideal location for your Biotech start-up

Infrastructure of the IZB

The Faculty ClubThe IZB Science Club

The conference rooms at the IZBRooms for meetings, seminars and networking

The hotel and restaurants at the IZBCampus hotel, restaurant and catering

The kindergarten Bio KidsA place for little researchers

The network events of the IZBBiotech Press-Lounge, IZBrunch and Life Sciences PitchDay

Downloads, videos & picture galleries in the IZB media library

Brochures of the IZB